Mezigdomide
Phase 2Small molecule
Bristol-Myers SquibbMezigdomide is one of 77 small molecule programs targeting Multiple Myeloma. It is currently in Phase 2.
3
Indications
20
Total Trials
16
Active Trials
76
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
258 competitors in Multiple Myeloma
#DrugCompanyPhaseTrials
1Belamaf
GSKPhase 3
Sarclisa
AAzienda U.S.L. 1 di Massa e Carrara
Phase 3
Biaxin
AbbViePhase 3
Xpovio
KKaryopharm Therapeutics Inc
Phase 3
Treanda
AAzurity Pharmaceuticals
Phase 3
Vepesid
AAvyxa
Phase 3
Mozobil
GGenzyme, a Sanofi Company
Phase 3
BLENREP
GGlaxo Dba Glaxosmithkline
Phase 3
Platinol
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Phase 3
Etentamig
AbbViePhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Multiple Myeloma10 trials
Show 7 more trials
Mezigdomide (CC-92480) Post Idecabtagene Vicleucel in Treating Patients With Relapsed Multiple Myeloma
Recruiting·—·Phase 1·NCT06048250·15 enrolled
A Phase 1, Multicenter, Open-label Study to Evaluate the Safety and Preliminary Efficacy of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma and Determine the Recommended Dose for Each Add-on Investigational Component
Recruiting·JJuno Therapeutics, Inc., a Bristol-Myers Squibb Company·Phase 1·NCT06121843·187 enrolled
Relapsed or Refractory Multiple Myeloma2 trials
Renal Impairment1 trial
Hepatic Impairment1 trial
5 more indications
Relapsed or Refractory1 trial
Multiple Myeloma, Refractory1 trial
Leukemia1 trial
KMT2A-rearranged1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Mezigdomide. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company